Ambrx Biopharma American Valuation
Based on Macroaxis valuation methodology, the firm cannot be evaluated at this time. Ambrx Biopharma American prevailing Real Value cannot be determined due to lack of data. The current price of Ambrx Biopharma American is $0.0. Our model approximates the value of Ambrx Biopharma American from analyzing the firm fundamentals such as operating margin of (483.51) %, and Return On Equity of -0.37 as well as examining its technical indicators and probability of bankruptcy.
Ambrx Biopharma Total Value Analysis
Ambrx Biopharma American is presently forecasted to have valuation of 1.56 B with market capitalization of 1.77 B, debt of 11.98 M, and cash on hands of 110.89 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Ambrx Biopharma fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
1.56 B | 1.77 B | 11.98 M | 110.89 M |
Ambrx Biopharma Investor Information
About 98.0% of the company shares are held by institutions such as insurance companies. The company had not issued any dividends in recent years. Ambrx Biopharma American had 1:1 split on the 12th of October 2023. Based on the key measurements obtained from Ambrx Biopharma's financial statements, Ambrx Biopharma American is not in a good financial situation at the moment. It has a very high risk of going through financial straits in April.Ambrx Biopharma Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Ambrx Biopharma has an asset utilization ratio of 2.78 percent. This suggests that the Company is making $0.0278 for each dollar of assets. An increasing asset utilization means that Ambrx Biopharma American is more efficient with each dollar of assets it utilizes for everyday operations.Ambrx Biopharma Ownership Allocation
The majority of Ambrx Biopharma American outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Ambrx Biopharma American to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Ambrx Biopharma. Please pay attention to any change in the institutional holdings of Ambrx Biopharma American as this could imply that something significant has changed or is about to change at the company.Ambrx Biopharma Profitability Analysis
The company reported the previous year's revenue of 4.09 M. Net Loss for the year was (67.06 M) with profit before overhead, payroll, taxes, and interest of 7.4 M.Ambrx Biopharma Growth Indicators
Investing in growth stocks can be very risky. If the company such as Ambrx Biopharma does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 38.6 M |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Other Consideration for investing in Ambrx Stock
If you are still planning to invest in Ambrx Biopharma American check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Ambrx Biopharma's history and understand the potential risks before investing.
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges |